Liminatus Pharma (LIMN) Cash & Equivalents (2024 - 2025)
Liminatus Pharma (LIMN) posted Cash & Equivalents of $337655.0 for Q4 2025, down 53.39% sequentially from $724502.0 in Q3 2025, and up 499.54% YoY from $56319.0 in Q4 2024.
Liminatus Pharma (LIMN) Cash & Equivalents (2024 - 2025) Analysis & Trends
Liminatus Pharma has reported Cash & Equivalents for 2 years, with the latest figure at $337655.0 in Q4 2025.
- Quarterly Cash & Equivalents rose 499.54% year-over-year to $337655.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $337655.0 (up 499.54% YoY) and the FY2025 annual result came in at $337655.0, up 499.54% from the prior year.
- Cash & Equivalents slipped to $337655.0 in Q4 2025 per LIMN's latest filing, from $724502.0 in the prior quarter.
- Over five years, Cash & Equivalents peaked at $724502.0 in Q3 2025 and troughed at $34098.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Liminatus Pharma | 256.03 Mn | 256.03 Mn | - | 3.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 337,655.00 |
| Sep 30, 2025 | 724,502.00 |
| Mar 31, 2025 | 34,926.00 |
| Dec 31, 2024 | 56,319.00 |
| Sep 30, 2024 | 46,979.00 |
| Jun 30, 2024 | 34,098.00 |